Who Paid My Doc
Michael Lin
Endocrinology, Diabetes & Metabolism San Gabriel, CA Medical Doctor
NPI 1285661819 CMS profile 194423
207 S Santa Anita Ave, Ste. P-20, San Gabriel, CA 91776
General payments
$348
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Michael Lin of San Gabriel, CA is reported in the CMS Open Payments database as having received $348 across 18 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 28th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $40 | 1 | |
| 2022 | General | $50 | 3 | |
| 2021 | General | $231 | 12 | |
| 2019 | General | $26 | 2 |
Beside peers
- Michael Lin
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Michael Lin were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Michael Lin | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $26 | $494 | $123–$2,253 | $163 |
| 2020 | $0 | $335 | $85–$1,841 | $114 |
| 2021 | $231 | $398 | $88–$1,981 | $132 |
| 2022 | $50 | $364 | $88–$1,568 | $149 |
| 2023 | $40 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $0 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 119 drugsPart D claims
16,269
Drug cost
$4,595,415
Branded share of claims
57.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 1,011 | $809,848 | |
| Rybelsus Semaglutide | Brand | 402 | $535,497 | |
| Ozempic Semaglutide | Brand | 298 | $430,388 | |
| Farxiga Dapagliflozin Propanediol | Brand | 413 | $339,462 | |
| Januvia Sitagliptin Phosphate | Brand | 397 | $309,404 | |
| Tradjenta Linagliptin | Brand | 209 | $154,527 | |
| Trulicity Dulaglutide | Brand | 126 | $134,862 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 98 | $130,008 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 354 | $128,704 | |
| Janumet Sitagliptin Phos/Metformin Hcl | Brand | 164 | $123,568 |
The 10 drugs with the highest cost, of 119 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$255,485
Medicare patients
1,132
Services billed
2,448
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 74% | |
| Chronic kidney disease | 50% | |
| Arthritis | 46% | |
| Ischemic heart disease | 37% | |
| Osteoporosis | 36% | |
| Heart failure | 21% | |
| COPD | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
18 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in California
Juan Frias
Endocrinology, Diabetes & Metabolism · San Diego, CA
Joselito Cabaccan
Endocrinology, Diabetes & Metabolism · San Jose, CA
Daniel Nadeau
Endocrinology, Diabetes & Metabolism · Newport Beach, CA
Yehuda Handelsman
Endocrinology, Diabetes & Metabolism · Tarzana, CA
Helen Baron
Endocrinology, Diabetes & Metabolism · Rancho Mirage, CA
Ken Fujioka
Endocrinology, Diabetes & Metabolism · San Diego, CA
Related records
Endocrinology, Diabetes & Metabolism in California
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.